Necrotizing Soft Tissue Infections clinical trials at UCSD
1 research study open to new patients

• Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections

  open to eligible people ages 12 years and up

  The purpose of this study is to determine whether AB103 is safe and effective in the treatment of patients with necrotizing soft tissue infections receiving standard of care therapy.

  San Diego, California and other locations

Last updated: July 22, 2018